You found a unicorn.

While this page doesn’t exist, the button below can take you home. 

Blog Masthead (above):

Hero Masthead (below):

Turn potential into action
Patient and loved one with Catalyst burst

H1 (below):

Your catalyst for better outcomes in rare disease

Our strength is in recognizing therapeutic potential, moving quickly, and doing everything humanly possible to improve the lives of people living with rare and difficult-to-treat conditions. 

Page Nav:

Card Grid:

Media & Content

Photo of Catalyst employees at a conference.

Passion and purpose drives proven success

We have a record of success turning promising innovations into marketed therapies and are always looking forward to the next opportunity to make a difference.

Photo of Catalyst employees at a conference.

Passion and purpose drives proven success

We have a record of success turning promising innovations into marketed therapies and are always looking forward to the next opportunity to make a difference.

Teardrop Break:

Background Block with Grid:

Catalyst Background

“Our passion is contagious. We really care about patients and what we do, and it inspires others to do more, too.”  

—Patty Flores, Area Marketing Director

Headshot of Catalyst employee, Patty Flores
Catalyst Background

“Our passion is contagious. We really care about patients and what we do, and it inspires others to do more, too.”  

—Patty Flores, Area Marketing Director

Headshot of Catalyst employee, Patty Flores
Catalyst Background

“Our passion is contagious. We really care about patients and what we do, and it inspires others to do more, too.”  

—Patty Flores, Area Marketing Director

Headshot of Catalyst employee, Patty Flores

Buttons:


Batch 01, below:

CTA block:

Up Next

Appx. 85 chars: Fingerpaint will make it look nicer for the actual Batch 1 delivery

Appx. 85 chars: Fingerpaint will make it look nicer for the actual Batch 1 delivery

Timeline:

  1. 2002

    Catalyst Founded

    Board of Directors formed.

  2. 2002

    CPP-109, a GABA analog

    In-licensed from Brookhaven National Laboratory for the treatment of cocaine and other addictions (development terminated in 2009)

  3. 2006

    CPRX listed on NASDAQ

  4. 2009

    CPP-115, a GABA aminotransferase (GABA-AT) inactivator

    In-licensed from Northwestern University (development terminated 2018)

  5. 2012

    FIRDAPSE® (amifampridine)

    Secured North American rights from BioMarin

  6. 2018

    FIRDAPSE

    Approved by the U.S. Food and Drug Administration (FDA) for symptoms of Lambert Eaton myasthenic syndrome (LEMS). FIRDAPSE is the first evidence-based product approved by the U.S. FDA for LEMS.

  7. 2019

    FIRDAPSE

    Catalyst and BioMarin agree to provide Catalyst with exclusive rights to FIRDAPSE in Japan and potential rights for parts of Asia and Central and South America.

  8. 2020

    FIRDAPSE

    Approved in Canada by Health Canada

    Sublicensed rights to Kye in Canada

    SERB S.A. acquired BioMarin’s overall license for FIRDAPSE and is Catalyst’s global licensor

  9. 2021

    FIRDAPSE

    Sublicensed rights in Japan to DyDo Pharma

  10. 2023

    FYCOMPA® (perampanel)

    Acquired US rights from Eisai

  11. 2023

    AGAMREE® (vamorolone)

    Acquired North American rights from Santhera
    Received US FDA approval for DMD

  12. 2024

    FIRDAPSE

    Received approval in Japan

  13. 2024

    AGAMREE

    Launched in the US
    Entered license agreement with Kye Pharmaceuticals in Canada

  14. 2025

    FIRDAPSE

    Commercially available in Japan.

  15. 2025

    AGAMREE

    Approved in Canada by Health Canada – first product approved in Canada for DMD

Tabs with Left bar Content border:

testing grid

also testing grid

When considering treatment options, which are limited, patients with LEMS should consult with a board-certified neurologist who specializes in neuromuscular diseases.
Amifampridine is the only evidence-based, FDA-approved treatment for adult patients with Lambert-Eaton Myasthenic Syndrome (LEMS).

When considering treatment options, which are limited, patients with LEMS should consult with a board-certified neurologist who specializes in neuromuscular diseases.
Amifampridine is the only evidence-based, FDA-approved treatment for adult patients with Lambert-Eaton Myasthenic Syndrome (LEMS).

some text about this image, should be in the second tab

Photo of Catalyst employees at a conference.

media content should work in this as well, probably

Icon / content:

testing heading inside this

For Patients For Heathcare Professionals

  • testing list inside icon content
  • this is new, and wasnt there before
  • oh nice it seems to be working

testing heading inside this

For Patients For Heathcare Professionals

Scrollable ISI:

Important Safety Information

What is AGAMREE? 
AGAMREE is a prescription medicine used to treat Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. 
 
IMPORTANT SAFETY INFORMATION 

Patients should not take AGAMREE if they are allergic to vamorolone or any of the inactive ingredients in AGAMREE. 
 
What is the most important information I should know about AGAMREE? 

  • Do not stop AGAMREE, or change the amount taken, without first checking with your healthcare provider. There may be a need for gradual dose reductions to decrease the risk of adrenal insufficiency crisis, which can be fatal.
  • There is an increased risk of infection when taking corticosteroids like AGAMREE. Tell your healthcare provider if the patient has had recent or ongoing infections or has recently received a vaccine. Seek immediate medical advice in the case of fever or other signs of infection. Some infections can be severe, and sometimes fatal. Patients should avoid exposure to chickenpox or measles; alert your healthcare provider immediately if exposure occurs. 
  • Corticosteroids, including AGAMREE, can cause an increase in blood pressure and water retention. Your healthcare provider may monitor for these increases during treatment.
  • There is an increased risk of developing a hole in the stomach or intestines in patients with certain gastrointestinal disorders when taking corticosteroids like AGAMREE.
  • Corticosteroids, including AGAMREE, can cause severe behavioral and mood changes. Seek medical attention if behavioral or mood changes develop.
  • Corticosteroids like AGAMREE may cause cataracts or glaucoma. Your healthcare provider should monitor for these conditions if AGAMREE treatment continues for more than 6 weeks. 
  • Immunizations should be up to date according to immunization guidelines prior to starting therapy with AGAMREE. Live‑attenuated or live vaccines should be administered at least 4 to 6 weeks prior to starting AGAMREE. Live‑attenuated or live vaccines should not be administered in patients taking AGAMREE.
  • Rare instances of severe allergic reaction have occurred in patients receiving corticosteroid therapy.

Before taking AGAMREE, tell your healthcare provider about all medical conditions, including if the patient:  

  • has decreased liver function 
  • is pregnant or planning to become pregnant. AGAMREE can harm an unborn baby. 
  • is breastfeeding or planning to breastfeed. AGAMREE may appear in breastmilk and could affect a nursing child. 


Certain medications can cause an interaction with AGAMREE. Tell your healthcare provider about all the medicines the patient takes, including prescription and over-the-counter medicines, dietary supplements, and herbal products. 
 
What are the possible side effects of AGAMREE?
The most common side effects with AGAMREE include facial puffiness (cushingoid features), psychiatric disorders, vomiting, weight gain, and vitamin D deficiency. These are not all the possible side effects of AGAMREE. 
 
Call your doctor for medical advice about side effects. 
 
Please see full Prescribing Information for additional Important Safety Information. 
 
To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals, Inc. at 1-844-347-3277 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

FW Image block:

A group of Catalyst employees

Supporting every step

For people on a Catalyst product, Catalyst Pathways offers personalized support for the healthcare journey, everything from disease education and access to patient communities and financial support.  

1/4 – 3/4 grid layout:

Summit Study sed do tempor incididue 30-35

Lorem ipsum dolor sit amet, consectetur adipiscing sed do tempor incididu 70 Lorem ipsum dolor sit amet, consectetur adipiscing sed do tempor incididu 70 Lorem ipsum dolor sit amet, consectetur adipiscing sed do tempor incididu 70

Summit Study sed do tempor incididue 30-35

Lorem ipsum dolor sit amet, consectetur adipiscing sed do tempor incididu 70 Lorem ipsum dolor sit amet, consectetur adipiscing sed do tempor incididu 70 Lorem ipsum dolor sit amet, consectetur adipiscing sed do tempor incididu 70

Summit Study sed do tempor incididue 30-35

Lorem ipsum dolor sit amet, consectetur adipiscing sed do tempor incididu 70 Lorem ipsum dolor sit amet, consectetur adipiscing sed do tempor incididu 70 Lorem ipsum dolor sit amet, consectetur adipiscing sed do tempor incididu 70

Summit Study sed do tempor incididue 30-35

Lorem ipsum dolor sit amet, consectetur adipiscing sed do tempor incididu 70 Lorem ipsum dolor sit amet, consectetur adipiscing sed do tempor incididu 70 Lorem ipsum dolor sit amet, consectetur adipiscing sed do tempor incididu 70


Batch 02, below:

Podcast block:

Catalyst Convos | Ep. 5

Fatherhood and Caring in Rare Disease Families

Contributors: Mark, Bill, Carrie Ostrea, Amy Grover
–:–
Fatherhood and Caring in Rare Disease Families
Catalyst Convos | Ep. 4

The Courage to Ask for Help in Rare Disease

Contributors: Maya Doyle, Jessica Campbell, Carrie Ostrea
–:–
The Courage to Ask for Help in Rare Disease
Catalyst Convos | Ep. 3

Bridging the Gap: Rural Healthcare Access in Rare Disease

Contributors: Darby Gavin, Terri Klein, Amy Grover, Carrie Ostrea
–:–
Bridging the Gap: Rural Healthcare Access in Rare Disease
Catalyst Convos | Ep. 2

Overcoming Healthcare Hurdles: Inspiring Stories from Laura Romero and Desiree Taliancich

Contributors: Laura Romero, Desiree Taliancich, Amy Grover
–:–
Overcoming Healthcare Hurdles: Inspiring Stories from Laura Romero and Desiree Taliancich
Catalyst Convos | Ep. 1

Empowered by Experience: Rich Daly on Epilepsy and Leadership

Contributors: Rich Daly, Amy Grover, Carrie Ostrea
–:–
Empowered by Experience: Rich Daly on Epilepsy and Leadership
Catalyst Convos

Welcome to Catalyst Convos: Empowering Stories and Expert Insights

Contributors: Amy Grover, Carrie Ostrea
–:–
Welcome to Catalyst Convos: Empowering Stories and Expert Insights

Slider block:

“I love the satisfaction I gain from knowing that I play an important role in ensuring 
that all patients receive the education and attention they need, which can significantly impact their lives.”

Leslie Oweazim

Patient Access Liaison

slide 2

slide 3

Image grid w/ custom mobile stacking:

Forbes America’s most successful midsize companies 2025 award logo
BioSpace best places to work award logo

Deloitte technology fast 500 2025 North America award logo

Rich Daly nominated as a Top 25 BioTech and Life Sciences Executives of 2025 by The Healthcare Technology Report

Video lightbox:


Batch 03, below:

Text – (Accordion with H2 tag)

Text – (Accordion with H3 tag)

Text – (Accordion with H4 tag)

Text – (Accordion with H5 tag)

Batch 04 ?, below: